---
document_datetime: 2025-09-23 14:04:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/alyftrek-epar-all-authorised-presentations_en.pdf
document_name: alyftrek-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7438688
conversion_datetime: 2025-12-22 08:53:27.392026
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength               | Pharmaceutical Form   | Route of Administration   | Immediate Packaging     | Pack size   |
|------------------|-------------------|------------------------|-----------------------|---------------------------|-------------------------|-------------|
| EU/1/25/1943/001 | Alyftrek          | 50 mg / 20 mg / 4 mg   | Film-coated tablet    | Oral use                  | blister (PCTFE/PVC/alu) | 84 tablets  |
| EU/1/25/1943/002 | Alyftrek          | 125 mg / 50 mg / 10 mg | Film-coated tablet    | Oral use                  | blister (PCTFE/PVC/alu) | 56 tablets  |